The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

GSK Plc won US approval for its drug to treat a deadly lung disease, ramping up competition with rival Sanofi.

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

The pharma company said it expects more approvals through the year following positive results from a Phase 3 trial.

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma ...

GSK has gained approval from the US Food and Drug Administration (FDA) for its monoclonal antibody, Nucala (mepolizumab), as ...

GSK (LSE:GSK) recently received FDA approval for Nucala for COPD treatment, potentially enhancing its market presence.

GSK plc has announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...